EPIRUS Biopharmaceuticals, Inc.
OTC: EPRSQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeff Kagy
- Employees
- 73
- Headquarters
- Boston, United States
- IPO year
- 2005
- Market cap
- $1.6K
- Website
- https://epirusbiopharma.com
Loading EPRSQ…
Loading profile data…Frequently asked questions about EPRSQ
What does EPIRUS Biopharmaceuticals, Inc. (EPRSQ) do?
EPIRUS Biopharmaceuticals, Inc. was a global pharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of biosimilar therapeutics. Its primary experimental compound was BOW015, a biosimilar counterpart to Remicade (infliximab), intended for the treatment of various inflammatory conditions. The company's dev...
Where does EPRSQ trade?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) trades on the Other OTC.
What sector is EPRSQ in?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of EPIRUS Biopharmaceuticals, Inc.?
Jeff Kagy is the chief executive officer of EPIRUS Biopharmaceuticals, Inc. (EPRSQ).
Where is EPIRUS Biopharmaceuticals, Inc. headquartered?
EPIRUS Biopharmaceuticals, Inc. is headquartered in United States.
Does EPRSQ pay a dividend?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EPRSQ go public?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) completed its initial public offering in 2005.